Literature DB >> 16879238

Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists.

E de Vries1.   

Abstract

Efficient early identification of primary immunodeficiency disease (PID) is important for prognosis, but is not an easy task for non-immunologists. The Clinical Working Party of the European Society for Immunodeficiencies (ESID) has composed a multi-stage diagnostic protocol that is based on expert opinion, in order to increase the awareness of PID among doctors working in different fields. The protocol starts from the clinical presentation of the patient; immunological skills are not needed for its use. The multi-stage design allows cost-effective screening for PID within the large pool of potential cases in all hospitals in the early phases, while more expensive tests are reserved for definitive classification in collaboration with an immunologist at a later stage. Although many PIDs present in childhood, others may present at any age. The protocols presented here are therefore aimed at both adult physicians and paediatricians. While designed for use throughout Europe, there will be national differences which may make modification of this generic algorithm necessary.

Entities:  

Mesh:

Year:  2006        PMID: 16879238      PMCID: PMC1809674          DOI: 10.1111/j.1365-2249.2006.03138.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Syndromes associated with immunodeficiency.

Authors:  J E Ming; E R Stiehm; J M Graham
Journal:  Adv Pediatr       Date:  1999

2.  Prevention and management of infections in patients without a spleen.

Authors:  R N Davidson; R A Wall
Journal:  Clin Microbiol Infect       Date:  2001-12       Impact factor: 8.067

Review 3.  [Immunology in medical practice. XXXIV. Screening for suspected immunodeficiency: Introduction].

Authors:  E de Vries; T W Kuijpers; M J van Tol; J W van der Meer; C M Weemaes; J J van Dongen
Journal:  Ned Tijdschr Geneeskd       Date:  2000-11-11

Review 4.  [Immunology in medical practice. XXXV. Screening of suspected immunodeficiency: diagnostic protocols for patients with opportunistic or recurrent severe infections, wasting and failure to thrive].

Authors:  E de Vries; T W Kuijpers; M J van Tol; J W van der Meer; C M Weemaes; J J van Dongen
Journal:  Ned Tijdschr Geneeskd       Date:  2000-11-11

Review 5.  Chronic mucocutaneous candidiasis.

Authors:  C H Kirkpatrick
Journal:  Pediatr Infect Dis J       Date:  2001-02       Impact factor: 2.129

Review 6.  Primary cellular immunodeficiencies.

Authors:  Rebecca H Buckley
Journal:  J Allergy Clin Immunol       Date:  2002-05       Impact factor: 10.793

Review 7.  Impaired interferon gamma-mediated immunity and susceptibility to mycobacterial infection in childhood.

Authors:  N Remus; J Reichenbach; C Picard; C Rietschel; P Wood; D Lammas; D S Kumararatne; J L Casanova
Journal:  Pediatr Res       Date:  2001-07       Impact factor: 3.756

Review 8.  Autoimmunity in human primary immunodeficiency diseases.

Authors:  Peter D Arkwright; Mario Abinun; Andrew J Cant
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

Review 9.  Primary immunodeficiency disorders: antibody deficiency.

Authors:  Mark Ballow
Journal:  J Allergy Clin Immunol       Date:  2002-04       Impact factor: 10.793

Review 10.  24. Clinical and laboratory assessment of immunity.

Authors:  James D Folds; John L Schmitz
Journal:  J Allergy Clin Immunol       Date:  2003-02       Impact factor: 10.793

View more
  43 in total

1.  Technical and diagnostic performance of five commercial anti-diphtheria toxoid IgG enzyme-linked immunosorbent assay kits.

Authors:  A Faruq; L Dadson; H Cox; F Alcock; A R Parker
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

2.  The European internet-based patient and research database for primary immunodeficiencies: results 2004-06.

Authors:  A-M Eades-Perner; B Gathmann; V Knerr; D Guzman; D Veit; G Kindle; B Grimbacher
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

3.  Early indicators of immunodeficiency in adults and children: protocols for screening for primary immunological defects.

Authors:  W A C Sewell; S Khan; P C Doré
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

4.  Immune globulin intravenous (human), 5% liquid gammaplex: for replacement therapy of primary humoral immunodeficiency.

Authors: 
Journal:  P T       Date:  2011-06

5.  Privigen immune globulin intravenous (human), 10% liquid.

Authors: 
Journal:  P T       Date:  2011-08

6.  Severe combined immunodeficiency in Greek children over a 20-year period: rarity of γc-chain deficiency (X-linked) type.

Authors:  Athanasios Michos; Marianna Tzanoudaki; Anna Villa; Silvia Giliani; George Chrousos; Maria Kanariou
Journal:  J Clin Immunol       Date:  2011-07-06       Impact factor: 8.317

7.  Comparison of seven commercial enzyme-linked immunosorbent assays for the detection of anti-diphtheria toxin antibodies.

Authors:  A A Zasada; W Rastawicki; K Śmietańska; N Rokosz; M Jagielski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-26       Impact factor: 3.267

8.  Reference ranges and cutoff levels of pneumococcal antibody global serum assays (IgG and IgG2) and specific antibodies in healthy children and adults.

Authors:  M A Rose; J Buess; Y Ventur; S Zielen; E Herrmann; J Schulze; R Schubert
Journal:  Med Microbiol Immunol       Date:  2013-03-26       Impact factor: 3.402

9.  Response to pneumococcal vaccination in mannose-binding lectin-deficient adults with recurrent respiratory tract infections.

Authors:  D A van Kessel; T W Hoffman; H van Velzen-Blad; P Zanen; G T Rijkers; J C Grutters
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

10.  A decreased frequency of regulatory T cells in patients with common variable immunodeficiency.

Authors:  Karina M Melo; Karina I Carvalho; Fernanda R Bruno; Lishomwa C Ndhlovu; Wassim M Ballan; Douglas F Nixon; Esper G Kallas; Beatriz T Costa-Carvalho
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.